$NUTX

These Two Healthcare Stocks Are Beating the Sector, They Still Look Cheap

Nutex Health (NUTX) and Elevance Health (ELV) have outperformed the healthcare sector in 2026, with NUTX up 36% and ELV up 11%. NUTX trades at a P/E of 9, while ELV is at 18, both below the sector average of 29.75. NUTX reported strong earnings growth, and ELV reaffirmed its 2026 guidance, highlighting stabilization in its cost structure.

Original reporting
Published Oct 9, 2026, 2:54 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 4:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
These Two Healthcare Stocks Are Beating the Sector, They Still Look Cheap — source image
Decision brief

The 30-second read

$NUTXBullishLow
01

Why it matters

Both stocks are portrayed as undervalued relative to peers, implying possible modest upside, but no new corporate events are disclosed.

02

Market read

Provides a valuation comparison that may prompt re‑rating of the two stocks, but limited trading urgency.

03

What to watch

Potential impact of ongoing healthcare policy changes and payer mix shifts not fully quantified.

Relevance 4/10Novelty 2/10Timing: none

Background

The article is a watch‑list style recap comparing Nutex Health (NUTX) and Elevance Health (ELV) to the broader healthcare sector, using previously released earnings data.

Company-level read

Ticker impact

$NUTXBullishMedium confidence
Context

Nutex Health is highlighted as a cheap, fast‑growing small‑cap hospital operator that has outperformed the healthcare sector YTD.

Expected impact

likely modest upside as investors re‑evaluate valuation gap

Evidence & confidence

No new corporate event; the piece is a recap of prior earnings and guidance, but the cheap valuation may attract fresh buying.

$ELVBullishMedium confidence
Context

Elevance Health is presented as an undervalued large‑cap insurer with solid dividend yield, buybacks and reaffirmed guidance.

Expected impact

potential modest upside from valuation re‑rating

Evidence & confidence

Again, no new corporate action; the article recaps prior results, but the highlighted dividend and buyback may spur incremental buying.

Market effects

The piece suggests the broader healthcare sector may be overvalued relative to these two cheaper peers.

U.S. healthcare equities could see modest re‑rating pressure.

Limited; focus is on U.S. listed health companies.

Counterpoint

Valuation gaps may reflect underlying risk; the cheap multiples could be justified by operational or regulatory headwinds.

Key entities

  • Nutex Health

    Small‑cap hospital operator

  • Elevance Health

    Large‑cap health insurer

Related articles

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$CVSMed

Aetna, Elevance, and Four Other Insurers Say the Medicare Advantage Star Rating System Is Broken — Now They Are Suing

CVS Health's Aetna subsidiary, along with Elevance Health, SCAN Health Plan, Alignment Healthcare, Healthfirst, and Centene, sued CMS over Medicare Advantage star ratings. They allege CMS used invalid measures, leading to lower ratings and $2B+ in lost bonus payments for Aetna. CMS has not responded. Ratings affect benefits for 4.2M Aetna members and $12.7B in annual bonuses.

Med

Elevance Earns $1.4 Billion Quarterly Profit as Membership Falls by 487,000 and Insurer Calls 2026 the Medicaid Trough

Elevance Health reported a $1.4B Q3 profit, up from $1.2B a year earlier, with 44.9M members, down 487K. The company expects 2026 to be the low point for Medicaid margins, with improvement in 2027. Elevance raised its full-year outlook to at least $29 per share, but is exiting some Medicaid markets and tightening spending. Medicaid work requirements begin in January 2027, potentially affecting 2.3M people.

$ELVMed

BofA raises Elevance stock price target to $500 on earnings beat

BofA Securities raised its price target for Elevance Health (ELV) to $500 from $480, citing a 10% Q3 earnings beat and raised 2026 guidance. The company's market cap is $94.2B, P/E ratio 19.62. BofA highlights seven 2027 tailwinds, including margin improvements and share buybacks. ELV reported Q3 EPS of $6.99 vs. $4.70 estimate, revenue of $50.4B vs. $49.32B estimate.